Dr. Jafari

 

 

Mahmoud Reza Jaafari

 

 

Professor of Pharmaceutics and Pharmaceutical Nanotechnology,

 

        [at]mums.ac.ir
[at]yahoo.com

 

Address: Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Phone: +98 513 8823255 (Office), +98 513 7619770 (Home)

Mobile: +98 915 3164001; Fax: +98 513 8823251

E-mail:  این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید or این آدرس ایمیل توسط spambots حفاظت می شود. برای دیدن شما نیاز به جاوا اسکریپت دارید ;

Website: http://www.mums.ac.ir/pharmacy/fa/drjaafari

Updated at:   6/28/2016                                                    

                                                       und Educational Background 

Pharm.D.: School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran, 1983-1988

Ph.D. in Pharmaceutics (Nanoliposomal drug and protein delivery): College of Graduate Studies and Research, Division of Pharmaceutical Sciences, University of Saskatchewan, Saskatoon, Canada, 1993-1998

Ph.D. Theses Title: Targeted drug delivery based on adhesion domains of immunoglobulin superfamily: P0 protein as a model

 

Visiting Associate Professor: Department of Biopharmaceutical Sciences and Pharmceutical Chemistry; School of Pharmacy, University of California at San Francisco (UCSF), 2006-2007 (Pharmaceutical Nanotechnology).

 

                                                                   Research Interests

Research Interests: Targeted drug delivery, nanomedicine, liposomal drug delivery, cancer treatment using nanoliposomes containing cytotoxic drugs, topical liposomes for the treatment of leishmaniasis, liposome based vaccination against cancer and leishmaniasis, liposome based nucleic acid delivery, peptide and protein formulation.

 

                                                                       Publications

1)      Foldvari M., Jaafari M.R., Mezei C., and Mezei M. (1998) Targeting of liposomes through immunoglobulin superfamily domains: P0 protein as a model. Drug Delivery, 5: 183-195.

2)      Jaafari M.R. and Foldvari M. (1999) P0 protein mediated targeting of liposomes to melanoma cells with high level of ICAM-1 expression. J. Drug Targeting, 7: 101-112.

3)      Jaafari M.R. and Foldvari M. (2002) Targeting of liposomes to human keratinocytes through adhesive peptides from immunoglobulin domains in the presence of IFN-gamma. Drug Delivery, 9:

4)      Jaafari M.R. and Foldvari M. (2002) Targeting of liposomes to melanoma cells with high level of ICAM-1 expression through adhesive peptides from immunoglobulin domains. J. Pharm.Sci. 91: 396-404.

5) Tafaghodi M., Sajadi Tabassi S.A., Jaafari M.R., (2004), Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int. J. Pharmaceutics, 280: 125-135.

6) Balali Mood M., Hefazi M., Mahmoudi M., Jalali I., Attaran D., Maleki M.,   Etezad Razavi M.R., Zare G., Jaafari M.R., Tabatabaee A., (2005) Evaluation of delayed toxic effects of sulfur mustard poisoning in severely intoxicated iranian veterans: A cross sectional study. Journal of Medical Chemical, Boilogical and Radiological Defense, 3: 1-32.

7) Sohrabi Y., Jaafari M.R., Miramin Mohammadi A., Eskandari S.E., Khamesipour A., (2004), Induction of cell mediated immunity against leishmaniasis using mannan coated liposomes encapsulated with autoclaved Leishmania major (ALM), International Proceeding Immunology, 125-128.

8) Foldvari M., Jaafari M.R., Radhi J., Segal D., (2005) Efficacy of the anti-adhesin, 2-O-propyl-octyl -Gal NAc (1-4) -Gal (Fimbrigal-P), in a rat oral candidiasis model. Antimicrob. Agents Chemother. 49:  2887-2894.

9) Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M, Razavi ME, Zare G, Tabatabaee A, Jaafari MR. (2005) Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol. 19 (6): 713-21.

10) Tafaghodi M., Sajadi Tabassi S.A., Jaafari M.R., (2006), Formulation, characterization and release studies of alginate microsphere encapsulated with tetanus toxoid. J. Biomater. Sci. Polymer Edn, 17 (8): 909-924.

11) Malaekeh-Nikouei B., Sajadi Tabassi S. A., Jaafari M. R. (2006) The Effect of Different Grades of PLGA on Characteristics of Microspheres Encapsulated with Cyclosporine A., Curr Drug Deliv. 2006 Oct; 3(4):343-9.

12) Jaafari M.R., Attieh Ghafarian A.,Farrokh-Gisour A., Samiei A., Tavassoti Kheiri M., Mahboudi F., Barkhordari F., Khamesipour A., McMaster W.R. (2006)Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice, Vaccine, 24: 5708-5717.

13) Tafaghodi M., Sajadi Tabassi S.A., Jaafari M.R., (2006), Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanous toxoid and CpG-ODN. Int. J. Pharm. 319: 37-43.

14) Malaekeh-Nikouei B., Sajadi Tabassi  S. A., Jaafari, M. R., Davies N. M., The effect of complexation on characteristics and drug release of PLGA microspheres loaded by cyclosporine-cyclodextrin complex, Journal of Drug Delivery Science and Technology, September/November 2006, 16 (5): 345-350.

15) Tafaghodi M., Jaafari M.R., Sajadi Tabassi S.A., (2006), Nasal immunization studies using liposomes loaded with tetanous toxoid and CpG-ODN. Eur. J. Pharm. Biopharm 64: 138-145.

16) Tabbakhian M., Tavakoli N., Jaafari M.R., Daneshamouz S., (2006) Enhancement of Follicular Delivery of Finasteride by Liposomes and Niosomes: 1. In Vitro Permeation and In Vivo Deposition Studies Using Hamster Flank and Ear Models, Int. J. Pharm. 323: 1-10.

17) M. R.  Jaafari, J. Behravan, J. Abde-Emami, F. Saghafi-Khadem,  M. Ramezani , (2006), Evaluation of leishmanicidal effect of Euphorbia bunjei extract by in vitro leishmanicidal assay using promastigote of Leishmania major, Int. J. Pharmacology 2 (5): 571-575.

18) Badiee A, Jaafari MR, Khamesipour A. (2007) Leishmania major: Immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp. Parasitol. 115(2): 127-134.

19) Iranshahi M, Arfa P, Ramezani M, Jaafari MR, Sadeghian H, Bassarello C, Piacente S, Pizza C. (2007) Sesquiterpene coumarins from Ferula szowitsiana and in vitro antileishmanial activity of 7-prenyloxycoumarins against promastigotes.

Phytochemistry. 2007 Feb; 68 (4): 554-61.

20) Jaafari M.R., Badiee A., Khamesipour A., Samiei A., Soroush D., Tavassoti Kheiri MT., Barkhordari F., McMaster W.R., Mahboudi F. (2007)The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome, Vaccine 25: 6107-6117 (2007).
21) Jaafari M.R., Hooshmand S., Samiei A., Hossainzadeh H., (2007), Evaluation of leishmaniacidal effect of Perovskia abrotanoides Karel root extract by in vitro leishmanicidal assay using promastigotes of Leishmania major, Pharmacologyonline 1: 299-303.
22) Monajjemi M., Afsharnezhad S., Jaafari M.R., Abdolahi T., Nikosade A., Monajemi H., (2007), NMR shielding and a thermodynamic study of the effect of environmental exposure to petrochemical solvent on DPPC, an important component of lung surfactant, Russian Journal of Physical Chemistry A, 81(12): 1956-1963.
23) Malaekeh-Nikouei B., Jaafari M. R., Sajadi Tabassi S. A., (2007) Preparation, characterization and mucoadhesive evaluation of chitosan coated liposomes containing cyclosporine A. Saudi Pharmaceutical Journal, 15 (3-4): 176-182.
24) Vahdati-Mashhadian N., Jaafari M.R., Nosrati A., (2007), Differential toxicity of rifampin on HEPG2 and HEP2 cells using MTT test and electron microscope. Pharmacologyonline 3: 405-413.
25) Monajjemi M., Afsharnezhad S., Jaafari M.R., Mirdamadi S, Mollaamin F., Monajemi H., (2008), Investigation of energy and NMR isotropic shift on the internal rotation barrier of O4 dihedral angle of the DLPC: A GIAO study, Chemistry 17 ( 1): 55-69.
 
26) Monajjemi M., Afsharnezhad S., Jaafari M.R., Mirdamadi S., Monajemi H., Mollaamin F., (2008), Theoretica study of solvent effects and NMR shielding tensors of DLPC,  Indonesian Journal of Chemistry 8 (1): 58-64.

27) Badiee A, Jaafari MR, Samiei A, Soroush D, Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol. 2008 Apr;15(4):668-74.

28) Tafaghodi M., Jaafari M.R., Sajadi Tabassi S.A., (2008) Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanous toxoid, Curr Drug Deliv. 5(2); 108-113.

29) Malaekeh-Nikouei B, Sajadi Tabassi SA, Jaafari MR. (2008 May) Preparation, characterization, and mucoadhesive properties of chitosan-coated microspheres encapsulated with cyclosporine a. Drug Dev Ind Pharm. 34 (5): 492-8.

30) Sajadi Tabassi S.A., Tafaghodi M., Jaafari M.R., (2008) Induction of high antitoxin titers against tetanous toxoid in rabbits by intranasal immunization with dextran microspheres, Int. J. Pharm. 2008 Aug 6;360(1-2):12-7.

31) Golmohammadzadeh S., Jaafari M.R., Khalili N., (2008) Evaluation of liposomal and conventional formulations on the human percutaneous absorption of octyl methoxycinnamate using stripping method. Journal of Cosmetic Science 59 (5): 385-398.

32) Malaekeh-Nikouei B., Jaafari M. R., Sajadi Tabassi S. A., Samiei A., (2008) The Enhancement of Immunosuppressive Effects of Cyclosporine A on Human T-Cells Using Fusogenic Liposomes, Colloids and Surface B: biointerfaces, 67: 238-244.

33) Hosseinzadeh H, Jaafari MR, Shamsara J. Selective inhibitory effect of adenosine A1 receptor agonists on the Selective inhibitory effect of adenosine A1 receptor agonists on the proliferation of human tumor cell lines. Iran Biomed J. 2008 Oct; 12(4):203-8.

34) Badiee A., Jaafari M.R., Khamesipour A., Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., McMaster W.R., Mahboudi F. (April 2009)The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63), Exp. Parasitol. 121 (4): 362-9.

35) Razzazan A, Saberi MR, Jaafari MR. (2008) Insights from the analysis of a predicted model of gp63 in Leishmania donovani. Bioinformation. 3 (3): 114-8.

36) Jaafari M.R., Bavarsad N, Fazly Bazzaz B.S., Samiei A., Dina Soroush,Ghorbani S., Lotfi Heravi M.M., Khamesipour A. (June 2009) The Effect of Topical Liposomes Containing Paromomycin Sulfate (PM) in the Course of Leishmania major Infection in Susceptible BALB/c Mice. Antimicrob. Agents Chemother. 53 (6): 2259-2265.

37) Abrishami M, Ganavati SZ, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina. 2009 May;29(5):699-703

38) Huang Z, Jaafari MR, Szoka FC Jr. 2009, Disterolphospholipids: Nonexchangeable Lipids and Their Application to Liposomal Drug Delivery. Angew Chem Int Ed  48: 4146-4149.

39) Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, Kheiri MT, Barkhordari F, McMaster WR, Mahboudi F. (2009) Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition. Colloids Surf B Biointerfaces. 74: 37-44.

40) Hadizadeh F, Moallem SA, Jaafari MR, Shahab M, Alahyari M, Rameshrad M, Samiei A. (2009) Synthesis and immunomodulation of human lymphocyte proliferation and cytokine (interferon-gamma) production of four novel malonitrilamides. Chem Biol Drug Des. 73(6):668-73.

41) Amin M, Jaafari MR, Tafaghodi M. (2009) Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surf B Biointerfaces. 74: 225-229.

42) Ebrahimnejad P, Dinarvand R, Sajadi SA, Atyabi F. Ramezani F, Jaafari MR, 2009, Preparation and Characterization of Poly Lactide-co-glycolide Nanoparticles of SN-38. PDA J. Pharm. Sci. Technol. 63: 512-520.

43) Ebrahimnejad P, Dinarvand R, Sajadi SA, Jaafari MR, Movaghari F, Atyabi F,  2009, Development and Validation of an Ion-pair HPLC Chromatography for Simultaneous Determination of Lactone and Carboxylate Forms of SN-38 in Nanoparticles. Journal of Food and Drug Analysis, 17 (4): 246-256.

44) Raji AR, Jaafari MR, 2009, Transmission electron microscopy study of the alveolar septum in adult camel, Indian Veterinary Journal, 86 (7): 719-721.

45) Hejazi H, Tasbihi M, Jaafari MR, Badiee A, Pestechian N, A Javadi A, Khamesipour A, 2010, The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice, Iranian J. Parasitol. 5 (1): 47-54.

46) Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M, Atyabi F. (2010 June), Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT29 cell lines. Nanomedicine. 6 (3): 478-85.

47) Tafaghodi M., Khamesipour A., Jaafari M.R. (Dec. 2010), Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental Autoclaved Leishmania major (ALM) and Quillaja saponins, Tropical Biomedicine 27(3): 639–650.

48) Tafaghodi M., Khamesipour A., Jaafari M.R., (2011 May), Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN, Parasitol Res. 108(5):1265-1273.

49) F. Vahedi, M.R. Jaafari, M.R. Mahmoudi, M. (Dec. 2010) The Effect of Using Cationic Liposomes Encapsulating pcDNA3.1+PA Plasmids on Humoral Immune Response in Mice, Iranian Journal of Immunology 7 (4): 210-216.

50) Iman M, Huang Z, Szoka FC, Jaafari MR, (2011 April 15), Characterization of the Colloidal Properties, In vitro Antifungal Activity, Antileishmanial Activity and Toxicity in Mice of a Distigmasterylhemisuccinoyl-glycero-phosphocholine Liposome-Intercalated Amphotericin B. Int J Pharm. 408(1-2):163-72.

51) Ebrahimnejad P, Dinarvand R, Jaafari MR, Sajadi SA, Atyabi F. (2011 Mar 15),  Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38. Int J Pharm. 406 (1-2): 122-7.

52) Tafaghodi M, Eskandari M, Khamesipour A, Jaafari MR (October 2011), Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis. Exp Parasitol. 129 (2): 107-14.

53) Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR.  (July 2012), Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomedicine: NBM,  8 (5): 692-701.

54) Pouran Layegh, Omid Rajabi, Mahmoud R. Jaafari, Parisa Emamgholi Tabar Malekshah, Toktam Moghiman, Hamee Ashraf, Roshanak Salari (2011) Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis. Journal of Parasitology Research, vol. 2011, Article ID 656523, 5 pages, 2011. doi:10.1155/2011/656523.

55) Shiva Golmohammadzadeh, Fatemeh Imani, Hossein Hosseinzadeh, Mahmoud Reza Jaafari (Nov-Dec 2011), Preparation, Characterization and Evaluation of Sun Protective and Moisturizing Effects of Nanoliposomes Containing Safranal. Iranian Journal of Basic Medical Sciences, 14 (6): 521-533.

56) Heravi Shargh V, Jaafari MR, Khamesipour A, Jalali SA, Firouzmand H, Abbasi A, Badiee A. (July 2012) Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis. Parasitol Res. 111(1): 105-114.

57) Adeli, M., Hakimpour, F., Sagvand, M., Jaafari, M.R., Kabiri, R., Moshari, Z. (2011) Supramolecular hybrid nanomaterials as drug delivery systems. Supramolecular Chemistry 23 (6) 411-418.

58) Shargh VH, Jaafari MR, Khamesipour A, Jaafari I, Jalali SA, Abbasi A, Badiee A. (June 6, 2012) Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine. 30 (26); 3957-64.

59) Fateme Hoseinipoor, Mahnaz Banihashemi, Mahmoud Reza Jaafari, ZariJavidi, Amir AbasAzarian,Vahid Mashayekhi Goyonlo, (2011) The Effect of Sun Radiation on the Course of Cutaneous Leishmaniasis in BALB/c Mice Iranian Journal of Basic Medical Sciences Vol. 14, No. 2 Mar-Apr 2011, 145-150.

60) Ali Khamesipour, Azam Abbasi, Alireza Firooz, Akram Mir Amin Mohammadi, Seyed Ebrahim Eskandari, Mahmoud R. Jaafari (March-April 2012) Treatment of Cutaneous Lesion of 20 Years’ Duration Caused By Leishmanization. Indian Journal of Dermatology 57(2): 148-150.

61)  Alavizadeh H, Badiee A, Khamesipour A, Jalali SA, Firouzmand H, Abbasi A, Jaafari MR. (Nov. 2012) The role of LPD nanoparticles containing CpG ODN in the course of infection induced by L. major in BALB/c mice. Exp Parasitol. 132: 313-319.

62) Bavarsad N, Bazzaz BS, Khamesipour A, Jaafari MR (2012 Oct) Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.  Acta Trop. 124 (1): 33-41. Epub 2012 Jun 29.

63) Badiee A, Khamesipour A, Samiei A, Soroush D, Shargh VH, Kheiri MT, Barkhordari F, Robert Mc Master W, Mahboudi F, Jaafari MR. 2012 Sep 13.The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol. 132: 403-409.  pii: S0014-4894(12)00261-5. doi: 10.1016/j.exppara.2012.09.001. [Epub ahead of print].

64) Ensieh Golali, Mahmoud Reza Jaafari, Ali Khamesipour, Azam Abbasi, Zahra Saberi, Ali Badiee (Sept. 2012) Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model. Iran J Basic Med Sci. 15 (5): 1032-1045.

65) Badiee A. Shargh VH, Khamesipour A, Jaafari MR, 2013 Jan 21, Micro/Nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine. 31(5):735-49. doi: 10.1016/j.vaccine.2012.11.068. Epub 2012 Dec 7. Review.

66) Rastgoo M, Hosseinzadeh H, Alavizadeh H, Abbasi A, Ayati Z, Jaafari MR. (2013 Apr) Antitumor Activity of PEGylated Nanoliposomes Containing Crocin in Mice Bearing C26 Colon Carcinoma. Planta Med.79(6):447-51. doi: 10.1055/s-0032-1328363. Epub 2013 Mar 28.

67) Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B, (June 2013) Docetaxel-loaded solid lipid nanoparticles: Preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci.; 102(6):1994-2004. doi: 10.1002/jps.23522. Epub 2013 Apr 5.

68) Hesamoddin Hoseinjani, Mahmoud Reza Jaafari, Ali Khamesipour, Azam Abbasi, Zahra Saberi, Ali Badiee, (2013) Evaluation of infection course in mice induced by L. major in presence of positively charged liposomes containing CpG ODN. Nanomed. J. 1(1): 30-40.

69) Pouran Layegh, Navid Mosallaei, Danial Bagheri, Mahmoud Reza Jaafari, Shiva Golmohammadzadeh, (2013) The efficacy of Isotretinoin-loaded solid lipid nanoparticles in comparison to Isotrex® on acne treatment . Nanomed. J. 1(1): 41-51.

70) Shiva Golmohammadzadeh, Mohsen Mokhtari, Mahmoud Reza Jaafari, (2012) Preparation, characterization and evaluation of moisturizing and UV protecting effects of topical solid lipid nanoparticles. Brazilian Journal of Pharmaceutical Sciences 48 (4): 683-690.

71) Shiva Golmohammadzadeh, Mohsen Mokhtari, Mahmoud Reza Jaafari, (2012) Improved photostability, reduced skin permeation and irritation of isotretinoin by solid lipid nanoparticles. Acta Pharm. 62: 547–562 DOI: 10.2478/v10007-012-0032-z.

72) Jalalian SH, Taghdisi SM, Shahidi Hamedani N, Kalat SA, Lavaee P, Zandkarimi M, Ghows N, Jaafari MR, Naghibi S, Danesh NM, Ramezani M, Abnous K. 2013 Oct 9, Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci. 50(2):191-7. doi: 10.1016/j.ejps.2013.06.015. Epub 2013 Jul 5.

73) Oskuee RK, Jaafari MR, Amel Farzad S, Ramezani M (June, 2012) In vitro leishmanicidal activity of Calotropis gigantea and its fractions against Leishmania major. Journal of Medicinal Plants Research  6 (23): 3977-3983. DOI: 10.5897/JMPR011.1530

74) Nasser Vahdati-Mashhadian, Mahmoud Reza Jaafari, Nasim Sharghi,  Toktam Sanati (2013) Protective Effects of Vitamin C and NAC on the Toxicity of Rifampin on Hepg2 Cells. Iranian Journal of Pharmaceutical Research. 12 (1): 141-146.

75) Hamid Mohammadpanah, Hossein Rastegar, Mohammad Reza Ramazani and Mahmoud Reza Jaafari, June 2013, Effects of Different Buffers and pH on the Stability of Recombinant Human Growth Hormone, BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA. Vol. 10(1), 193-203.

76) Firouzmand H, Badiee A, Khamesipour A, Heravi Shargh V, Alavizadeh SH, Abbasi A, Jaafari MR. Dec. 2013, Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).  Acta Trop. 128(3): 528-35. doi: 10.1016/j.actatropica.2013.07.021. Epub 2013 Aug 2.

77) Amin M, Badiee A, Jaafari MR. 2013 Dec 31, Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm. 458(2): 324-33. doi: 10.1016/j.ijpharm.2013.10.018. Epub 2013 Oct 19.

78) Chavoshian O, Biari N, Badiee A, Khamesipour A, Abbasi A, Saberi Z, Jalali SA, Jaafari MR. Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice. Iran J Basic Med Sci. 2013 Sep; 16 (9):965-72.

79) Jabini R, Jaafari MR, Vahdati Hasani F, Ghazizadeh F, Khamesipour A, Karimi G. March 2015, Effects of Combined Therapy with Silymarin and Glucantime on Leishmaniasis Induced by Leishmania major in BALB/c Mice. Drug Res. 65 (3): 119-124.

80) Shariat S, Badiee A, Jaafari MR, Mortazavi SA. 2014 Winter, Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer. Iran J Pharm Res. 2014 Winter; 13(Suppl): 15-25.

81) Moosavian Kalat SA, Khamesipour A, Bavarsad N, Fallah M, Khashayarmanesh Z, Feizi E, Neghabi K, Abbasi A, Jaafari MR. 2014 Aug, Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice. Exp Parasitol. 143:5-10. doi: 10.1016/j.exppara.2014.04.013. Epub 2014 Apr 26.

82) Alavizadeh SH, Badiee A, Golmohammadzadeh S, Jaafari MR, 2014 Oct 1, The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. Int J Pharm. 473(1-2): 326-33. doi: 10.1016/j.ijpharm.2014.07.020. Epub 2014 Jul 19.

83) Reza Kazemi Oskuee, Mahmoud Reza Jaafari, Sara Amani, Mohammad Ramezani (July 2014) Evaluation of leishmanicidal Effect of Euphorbia erythadenia extract by in vitro leshmanicidal assay using Promastigotes of Leishmania major. Asian Pac J Trop Biomed 2014; 4(Suppl 2): S905-S907.

84) Eskandari F, Talesh GA, Parooie M, Jaafari MR, Khamesipour A, Saberi Z, Abbasi A, Badiee A. Immunnoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis. Exp Parasitol. 2014 Sep 19. pii: S0014-4894(14)00206-9. doi: 10.1016/j.exppara.2014.08.016. [Epub ahead of print].

85) Shariat S, Badiee A, Jalali SA, Mansourian M, Yazdani M, Mortazavi SA, Jaafari MR. 2014 Dec 1, P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. Cancer Lett. 355(1): 54-60. doi: 10.1016/j.canlet.2014.09.016. Epub 2014 Sep 16.

86) Sahebkar A, Badiee A, Ghayour-Mobarhan M, Goldouzian SR, Jaafari MR. 2014 Oct 1, A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes. Colloids Surf B Biointerfaces.;122: 645-52. doi: 10.1016/j.colsurfb.2014.07.045. Epub 2014 Aug 12.

87) Mansourian M, Badiee A, Jalali SA, Shariat S, Yazdani M, Amin M, Jaafari MR. (Nov., 2014) Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol Lett. 162 (1): 87-93.

88) A. Kazemi-Beydokhti, S. Zeinali Heris, M. R. Jaafari, S. Nikoofal-Sahlabadi,  M. Tafaghodi2, M. Hatamipoor, Dec. 2014,  Microwave functionalized single-walled carbon nanotube as nanocarrier for the delivery of anticancer drug cisplatin: in vitro and in vivo evaluation,  J. DRUG DEL. SCI. TECH., 24 (6) 572-578.

89) Hanafi-Bojd MY, Jaafari MR, Ramezanian N, Xue M, Amin M, Shahtahmasbi N, Malaekeh-Nikouei B. (Jan. 2015) Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Eur J Pharm Biopharm. 89: 248-258. doi: 10.1016/j.ejpb.2014.12.009. Epub 2014 Dec 13.

90) Khameneh B, Halimi V, Jaafari MR, Golmohammadzadeh S. 2015 Jan, Safranal-loaded solid lipid nanoparticles: evaluation of sunscreen and moisturizing potential for topical applications. Iran J Basic Med Sci. 18(1):58-63.

91) Sahebkar A, Badiee A, Hatamipour M, Ghayour-Mobarhan M, Jaafari MR. (2015 Mar 7), Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia. Colloids Surf B Biointerfaces.129: 71-78. doi: 10.1016/j.colsurfb.2015.03.012. [Epub ahead of print].

92) Amin Kazemi-Beydokhti, S. Zeinali Heris, M.R. Jaafari (2015) Experimental investigation of thermal conductivity of medical nanofluids based on functionalised single-wall carbon nanotube and conjugated cisplatin, Micro & Nano Letters, 10 (5): 241-247. doi: 10.1049/mnl.2014.0593.

93) Nourbakhsh M, Jaafari MR, Lage H, Abnous K, Mosaffa F, Badiee A, Behravan J., 2015 Apr; Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci. 18(4):385-92.

94) Nourbakhsh M, Behravan J, Lage H, Abnous K, Mosaffa F, Badiee A, Jaafari MR, Winter 2015, Nanolipoparticles-mediated MDR1 siRNA delivery: preparation, characterization and cellular uptake. Nanomedicine Journal. 2(1): 39-45.

95) Nouri HR, Varasteh A, Jaafari MR, Davies JM, Sankian M., 2015 Jul; Induction of a Th1 immune response and suppression of IgE via immunotherapy with a recombinant hybrid molecule encapsulated in liposome-protamine-DNA nanoparticles in a model of experimental allergy. Immunol Res. 62(3): 280-91. doi: 10.1007/s12026-015-8659-8

 

96) Shariat Sh, Badiee A, Jalali SA, Mansourian M, Mortazavi SA, Jaafari MR. 2015 Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects. Iran J Basic Med Sci. 18 (5):506-513.

97) Khameneh B, Jaafari MR, Hassanzadeh-Khayyat M, Varasteh A, Chamani J, Iranshahi M, Mohammadpanah H, Abnous K, Saberi MR. 2015 Sep; Preparation, characterization and molecular modeling of PEGylated human growth hormone with agonist activity. Int J Biol Macromol. 80:400-9. doi: 10.1016/j.ijbiomac.2015.06.037. Epub 2015 Jun 23.

98) Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. 2015 Sep; Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. J Cosmet Dermatol. 14(3):174-7. doi: 10.1111/jocd.12152.

99) Moosavian SA, Jaafari MR, Taghdisi SM, Mosaffa F, Badiee A, Abnous K. 2015 Jun; Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iran J Basic Med Sci. 18(6):576-86.

100) Teymouri M, Farzaneh H, Badiee A, Golmohammadzadeh S, Sadri K, Jaafari MR. 2015 Dec 1; Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. Eur J Pharm Sci.; 80: 66-73. doi: 10.1016/j.ejps.2015.08.011.

101) Nikpoor AR, Tavakkol-Afshari J, Gholizadeh Z, Sadri K, Babaei MH, Chamani J, Badiee A, Jalali SA, Jaafari MR. Nov. 10, 2015; Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. Int J Pharm. 495(1):162-170. doi: 10.1016/j.ijpharm.2015.08.048.

102) Arabi L, Badiee A, Mosaffa F, Jaafari MR. 2015 Dec 28;  Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. J Control Release. 220(Pt A): 275-86. doi: 10.1016/j.jconrel.2015.10.044.

103) Amin M, Mansourian M, Koning GA, Badiee A, Jaafari MR, Ten Hagen TL. 2015 Dec 28;Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. J Control Release. 220(Pt A): 308-15. doi: 10.1016/j.jconrel.2015.10.039.

104)  Sadri K, Momenypoor S, Dabbagh Kakhki VR, Sadeghi R, Aryana K, Johari Daha F, Zakavi SR, Jaafari MR. 2015 Fall, Nano Liposomes Labeled with 99mTc-HMPAO, a Novel Agent for Blood Pool Imaging. Iran J Pharm Res.; 14 (4): 981-988.

105) Rahimi HR, Jaafari MR, Mohammadpour AH, Abnous K, Ghayour-Mobarhan M, Ramezanzadeh E, et al. 2015, Curcumin: Reintroduced Therapeutic Agent from Traditional Medicine for Alcoholic Liver Disease. Asia Pac J Med Toxicol. 4: 25-30.

106) Ghaffari-Nazari H, Tavakkol-Afshari J, Jaafari MR, Tahaghoghi-Hajghorbani S, Masoumi E, Jalali SA. 2015 Nov 10, Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice. PLoS One.; 2015 Nov 10;10(11):e0142563. doi: 10.1371/journal.pone.0142563. eCollection 2015.

107) Marzban E, Alavizadeh SH, Ghiadi M, Khoshangosht M, Khashayarmanesh Z, Abbasi A, Jaafari MR. 2015 Dec 1, Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies. Colloids Surf B Biointerfaces.; 136: 885-891. doi: 10.1016/j.colsurfb.2015.10.046.

108) Alavizadeh SH, Akhtari J, Badiee A, Golmohammadzadeh S, Jaafari MR. 2016 Mar, Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Expert Opin Drug Deliv. 13(3):325-36. doi: 10.1517/17425247.2016.1121987.

109) Mahboobeh NASSERI, Hossein AROUIEE, Shiva GOLMOHAMMADZADEH, Mahmoud Reza JAAFARI, Hossein NEAMATI, 2015, Antifungal Effects of Zataria multiflora Essential Oil on the Inhibitory Growth of some Postharvest Pathogenic Fungi, Not Sci Biol, 7(4): 412-416. DOI: 10.15835/nsb.7.4.9650.

110) Salarini R, Sahebkar A, Mirzaei HR, Jaafari MR, Riahi MM, Hadjati J, Asrami MO, Fdaee S, Salehi R, Mirzaei H., 2015 Dec 6., Epi-drugs and Epi-miRs: Moving beyond current cancer therapies. Curr Cancer Drug Targets. 2015 Dec 6. [Epub ahead of print].

111) Mirzaei H, Sahebkar A, Avan A, Jaafari MR, Salehi R, Salehi H, Baharvand H, Rezaei A, Hadjati J, Pawelek JM1, Mirzaei HR. Application of Mesenchymal Stem Cells in Melanoma: a potential therapeutic strategy for delivery of targeted agents. Curr Med Chem. 2015 Dec 17. [Epub ahead of print].

112) Mobasheri M, Attar H, Rezayat Sorkhabadi SM, Khamesipour A, Jaafari MR., 2015 Dec 24; Solubilization Behavior of Polyene Antibiotics in Nanomicellar System: Insights from Molecular Dynamics Simulation of the Amphotericin B and Nystatin Interactions with Polysorbate 80. Molecules. 21(1): 1-26. pii: E6. doi: 10.3390/molecules21010006.

113) Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Tafaghodi M, Hojatizade M, Abbasi A, Badiee A. 2015 Dec; Cationic Immune Stimulating Complexes Containing Soluble Leishmania Antigens: Preparation, Characterization and in Vivo Immune Response Evaluation. Iran J Immunol. 12(4):274-87. doi: IJIv12i4A5.

114) YahyaHanafi-Bojd M, Jaafari MR, Ramezanian N, Abnous K, Malaekeh-Nikouei B. Co-delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy. Curr Drug Deliv. 2015 Dec 30. [Epub ahead of print].

115) Moosavian SA, Abnous K, Badiee A, Jaafari MR. 2016 Mar 1; Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Colloids Surf B Biointerfaces. 139: 228-236. doi: 10.1016/j.colsurfb.2015.12.009.

116) Mirzaei H, Sahebkar A, Jaafari MR, Hadjati J, Javanmard SH, Mirzaei HR, Salehi R. PiggyBac as a novel vector in cancer gene therapy: current perspective. Cancer Gene Ther. 2016 Jan 8. doi: 10.1038/cgt.2015.68. [Epub ahead of print].

117) Ahmad Mehravaran, Mahmoud Reza Jaafari, Seyed Amir Jalali, Ali Khamesipour, Reza Ranjbar , Mansure Hojatizade , Ali Badiee; Feb 2016 The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice. Iran J Basic Med Sci, 19 (2): 178-186.

118)  Mohammad Reza Ghazanfari, Mehrdad Kashefi, Mahmoud Reza Jaafari, (May 1, 2016), Modeling and optimization of effective parameters on the size of synthesized Fe3O4 superparamagnetic nanoparticles by coprecipitation technique using response surface methodology. Journal of Magnetism and Magnetic Materials, 405 : 88–96.

119) Zahmatkeshan M, Gheybi F, Rezayat SM, Jaafari MR. 2016 Apr 30, Improved drug delivery and therapeutic efficacy of PEGylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Eur J Pharm Sci. 86: 125-35. doi: 10.1016/j.ejps.2016.03.009.

120) Razavi-Azarkhiavi K, Jafarian AH, Abnous K, Razavi BM, Shirani K, Zeinali M, Jaafari MR, Karimi G. The Comparison of Biodistribution, Efficacy and Toxicity of Two PEGylated Liposomal Doxorubicin Formulations in Mice Bearing C-26 Colon Carcinoma: a Preclinical Study. Drug Res (Stuttg). 2016 Mar 29. [Epub ahead of print].

121) Akhtari J, Rezayat SM, Teymouri M, Alavizadeh SH, Gheybi F, Badiee A, Jaafari MR. 2016 May 1,Targeting, biodistributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. Int J Pharm. 505: 89-95. doi: 10.1016/j.ijpharm.2016.03.060.

122) Fakhraee F, Badiee A, Alavizadeh SH, Jalali SA, Chavoshian O, Khamesipour A, Mahboudi F, Jaafari MR. May 2016, Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L .major dissemination to the spleen in BALB/c mice-based experimental setting. Acta Trop. 2016 Apr 6. 159: 211–218 doi: 10.1016/j.actatropica.2016.04.004.

                                                                      Presentations

1) Foldvari, M. and Jaafari, M.R. 1994. Effect of synthetic P0-oligopeptides on the cell adhesion properties of P0 protein reconstituted into liposomes. Pharmaceutical Research, 11(10) S-328 (Congress of American Association of Pharmaceutical Sciences, SanDiego, USA, November 6-10, 1994).

2) Jaafari, M.R. and Foldvari, M. 1997. Adhesive properties of P0 protein reconstituted into liposomes with different human melanoma cell lines. Pharmaceutical Research, 14(11) S-157 (Congress of American Association of Pharmaceutical Sciences, Boston, USA, November 2-6, 1997).

3) Jaafari, M.R. and Foldvari, M. 1997. Inhibition of adherence of jurkat T cells to keratinocytes by LFA-1 derived and RGD peptides. Pharmaceutical Research, 14(11) S-312 (Congress of American Association of Pharmaceutical Sciences, Boston, USA, November 2-6, 1997).

4) Jaafari, M.R. and Foldvari, M. 1998. Liposome targeting to melanoma cells through adhesive peptides from immunoglobulin (Ig) domains. Pharmaceutical Research, 15(11) Supplement (Congress of American Association of Pharmaceutical Sciences, San Francisco, USA, November 15-19, 1998).

5) Foldvari, M. and Jaafari, M.R. 1997. Studies of adhesive properties of myelin P0 protein derived peptides. In: Juurlink, B.H.J., Devon, R.M., Doucette, J.R., Nazarali, A.J  Cell Biology and Pathology of Myelin : Evolving Biological Concepts and Therapeutic Approaches (Altschul Symposia Series: Cell Biology and Pathology of Myelin : Evolving Biological Concepts and Therapeutic Approaches, Saskatoon, Canada June 27-29, 1996).

6) Jaafari M.R., Khamesipour A., Hemedivafa F., koushkbaghy M. 2001, Inducing cell- mediated immunity in BALB/C mice using liposomes encapsulated with crude Leishmania antigens (CLA) (WORLDleish 2, MAY 20-24, 2001, Crete, Greece).

7) Jaafari M.R., Sadri K., Arefee A., Amani M., Mahboudi  F. Protection of BALB/c mice against cutaneous leishmaniasis by immunization with recombinant leishmania major surface glycoprotein (rGP63)/ liposomes  (Pharmacy and Pharmaceutical Sciences World Congress, Nice, France, Sept. 2002).

8) M. Tabbakhian, S. Daneshamouz, M. R. Jaafari, N. Tavakoli,  Preparation and Characterization of niosomes containing finasteride  (AAPS American Association of pharmaceutical Sciences annual meeting and expositon Toronto, Canada  Nov. 10-15, 2003).

9) M. R. Jaafari, A. Arefee, K. Sadri, M. Amani and F. Mohboudi, Vaccination of BALB/c mice against cutaneous leishmaniasis using fusogenic liposomes incorporated with recombinant major surface glycoprotein of leishmania (rGP63), Journal of Pharmacy and Pharmacology, 55: S-69 (2003), (British Pharmaceutical Conference, Harrogate, UK, Sept. 15-17, 2003).

10) M. R. Jaafari, A. Ghafarian, A. Farrokh-Gisour, M. Amani and F. Mahboudi, 2003,Vaccination of BALB/c mice against cutaneous leishmaniasis using neutral liposomes incorporated with recombinant major surface glycoprotein of  of leishmania (rGP63). Sixth Int. Conference, Liposome Advances: Progress in drug and vaccine delivery, School of Pharmacy, University of London, Dec. 15-19, 2003, London, UK, Abstract book: page 97.

11) Y. Sohrabi, M. R. Jaafari, A., A. Miramin Mohammadi and A. Khamesipour, Induction of cell mediated immunity  against leishmaniasis using mannan coated liposomes containing autoclaved leishmania major. Sixth Int. Conference, Liposome Advances: Progress in drug and vaccine delivery, School of Pharmacy, University of London, Dec. 15-19, 2003, London, UK, Abstract book: page 128.

12) A. Khamesipour, M. R. Jaafari, A., A. Miramin Mohammadi and Y. Sohrabi, 2003,Vaccination of BALB/c mice  with liposomes/autoclaved leishmania major composed of different phospholipids. Sixth Int. Conference, Liposome Advances: Progress in drug and vaccine delivery, School of Pharmacy, University of London, Dec. 15-19, 2003, London, UK, Abstract book:  page 108.

13) M. R. Jaafari, A. Ghafarian, A. Farrokh-Gisour, M. Amani and F. Mahboudi, Vaccination of BALB/c mice against cutaneous leishmaniasis using mannan coated positively charged liposomes incorporated with recombinant major surface glycoprotein of leishmania (rGP63). 9th Liposome Research Days, Above and Beyond, May 11-15, 2004, Hsinchu, Taiwan, Abstract book:  page 110.

14) Tafaghodi M., Sajadi S.A., Jaafari M.R., Zakavi S.R., Momen-Nejad M.  Gamma-scintigraphic evaluation of the clearance characteristics of microspheres in the human nose, 2nd Pharmaceutical Sciences World Congress, The Global Translational of science into Drug Development in Advancing Therapy, May 30-June 3, 2004, Kyoto, Japan, Abstract book: page 253.

15) Sajadi Tabassi S.A., Tafaghodi M., Jaafari M.R., Dextran microspheres as a potential delivery systems for nasa immunization- in vitro and in vivo characterization, Proc. International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nuremberg, 15-18 March 2004., page 501-502.

16) Jaafari, M.R. Badiee A. Samiei A., Soroush D., Khamesipour A., Amani M., Mahboudi F., Vaccination of BALB/c Mice against cutaneous leishmaniais (CL) using lipsomes containing recombinant major surface glycoprotein of leishmania (rGP63) and CPG ODNs, WORLDleish 3, April 10-15, 2005, Terrasini, Palermo, Italy Abstract book: page: 257.

 

17) Sohrabi Y., Jaafari M.R., Miramin Mohammadi A.,  Eskandari S.E., Khamesipour A., Evaluation of immune response against leishmaniasis induced by liposomes containing freeze/thawed thimrosal treated L. major (KLM) in C57BL/6 MICE, WORLDleish 3, April 10-15, 2005, Terrasini, Palermo, Italy Abstract book: page: 279.

18) Badiee A., Jaafari M.R., Samiei A., Soroush D., Webb J., Khamesipour A., Immunization of BALB/c mice against cutaneous leishmaniasis (CL) using lipsomes containing rLmSTI1 and CPG ODNs, WORLDleish 3, April 10-15, 2005, Terrasini, Palermo, Italy Abstract book: page: 238.

 

19) Sohrabi Y., Jaafari M.R., Miramin Mohammadi A.,  Eskandari S.E., Khamesipour A., 2005, Evaluation of immune response against leishmaniasis in resistance C57BL/6 mice immunized with liposomes containing autoclaved leishmania major with BCG. Cell. Mol. Biol. Lett., 10 (Supp.): 98.

20) Ramezani M., Emamy J.A., Jaafari M.R., Behravan M., Evaluation of leishmaniacidal effect of Euphorbia bunjei extract by in vitro leishmaniacidal assay using promastigotes of L. major, AHAT BSAS International Conference, Nov. 14-18, 2005, Khon Kaen, Thailand, P20-21.

21) Sajadi Tabassi S.A., Tafaghodi M., Jaafari M.R. Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid, 9th Commonwealth Pharmaceutical Association Conference, 1-5 August 2007, Kuala Lumpur, Malaysia, Abstract book, P 116.

22) Mahmoud R Jaafari, Zhaohua Huang, Francis C Szoka, New lipids for liposome construction and use in the treatment of cancer. International Liposome Society 2007 Annual Meeting, Liposome Advances: Progress in Drug and Vaccine Delivery, School of Pharmacy, University of London, Dec. 8-11, 2007, London, UK, Abstract book:  page 28 (Podium Presentation)

23) M. R. Jaafari, A. Badiee, A. Khamesipour, A. Samiei, M. Tavassoti Kheiri, F. Barkhordari, and F. Mohboudi, Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of leishmania (rGP63): The role of bilayer composition, International Liposome Society 2007 Annual Meeting, Liposome Advances: Progress in Drug and Vaccine Delivery, School of Pharmacy, University of London, Dec. 8-11, 2007, London, UK, Abstract book:  page 65 (Poster Presentation).

24) Zhaohua Huang, Mahmoud R Jaafari, Francis C Szoka, Evaluation of nanolipid formulations as drug carriers, 9th US-Japan Symposium on Drug Delivery Systems, The Westin  Maui, Lahaina, Maui, Hawaii, December 16-20, 2007.

25) M. R. Jaafari, A. Khamesipour, A. Samiei, D. Soroush, M. Tavassoti Kheiri, F. Barkhordari, and F. Mohboudi, Vaccination of BALB/c mice against cutaneous leishmaniasis using LPD nanoparticles containing rLmaCIN prepared with CpG Oligodeoxynucleotides. 11th Liposome Research Days Conferences, Innovation from Liposome, July 19-22, 2008, Yokohama, Japan, Abstract Book:  page 211.

26) M. R. Jaafari, A. Badiee, A. Khamesipour, A. Samiei, D. Soroush, M. Tavassoti Kheiri, F. Barkhordari, and F. Mohboudi, The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of leishmania (rGP63). 11th Liposome Research Days Conferences, Innovation from Liposome, July 19-22, 2008, Yokohama, Japan, Abstract Book:  page 216.

27) N. Bavarsad, M. R. Jaafari, S. Fazly Bazaz, M. M. Lotfi Heravi, S. Ghorbani, A. Samiei, D. Soroush, A. Khamesipour, Activity of topical liposomes containing paromomycin sulfate against experimental cutaneous leishmaniasis. 11th Liposome Research Days Conferences, Innovation from Liposome, July 19-22, 2008, Yokohama, Japan, Abstract Book:  page 122.

28) B. Malaekeh-Nikouei, M. R. Jaafari, S. A. Sajadi Tabassi, A. Samiei, The effect of phospholipid type and size on immunosuppressive activities of liposomes encapsulated with Cyclosporine A. 11th Liposome Research Days Conferences, Innovation from Liposome, July 19-22, 2008, Yokohama, Japan, Abstract Book:  page 208.

29) Maryam Iman, Zhaohua Huang, Francis C. Szoka, Jr.and Mahmoud R. Jaafari Colloidal, relative toxicity and in vivo antileishmanial properties of liposome-intercalated Amphotericin B prepared from distigmasterylhemisuccinoyl-glycero-phosphocholin, International Liposome Research Days and Lipids, Liposomes and Membrane Biophysics, Aug. 4-8, 2010,  University of British Colombia, Vancouver, Canada.

30) Mohamadreza Amin, Ali Badiee, Mahmoud Reza Jaafari, Biodistribution of RGD-targeted liposomes containing doxorubicin in mice bearing C-26 colon Carcinoma, ESF-UB Conference in Biomedicine on Nanomedicine: Reality Now and Soon, 23-28 October 2010 Sant Feliu, Spain.

31) Mahmoud R. Jaafari, Zhaohua Huang  & Francis C. Szoka, Sterol Modified Lipids for Improved Liposome Anticancer Drug Formulation, 3rd Conference on Nanostructures, March 10-12, 2010, Sharif University of Technology, International Campus, Kish Island, Iran.

32) F. Hoda Alavizadeh, Mahmoud R. Jaafari, Ali Badiee, Ali Khamesipour, Amir Jalali, Azam Abbasi, Evaluation of lesion development and type of immune response generated in mice inoculated with L.major mixed with LPD nanoparticles containing CpG ODN, 3rd Conference on Nanostructures, March 10-12, 2010, Sharif University of Technology, International Campus, Kish Island, Iran.

33) Maryam Iman, Zhaohua Huang, Francis C. Szoka, Jr.and Mahmoud R. Jaafari, Nanoliposomes prepared from distigmasterylhemisuccinoyl-glycero-phosphocholin: Novel Amphotericin B nano-carrier with low toxicity, 12th Iranian Pharmaceutical Sciences Congress, Aug. 2-5, 2010, Zanjan, Iran.

34) Mohamadreza Amin, Ali Badiee, Mahmoud Reza Jaafari, Biodistribution of RGD-targeted liposomes containing doxorubicin in mice bearing C-26 colon Carcinoma, ESF-UB Conference in Biomedicine on Nanomedicine: Reality Now and Soon, 23-28 October 2010, Hotel Eden Roc, Sant Feliu de Guixols, Spain.

35) Mohamadreza Amin, Ali Badiee, Mahmoud Reza Jaafari, Antitumor efficacy of RGD-targeted liposomes containing doxorubicin in mice bearing C-26 colon Carcinoma. International Liposome Society 2011 Annual Meeting, Liposome Advances: Progress in Drug and Vaccine Delivery, School of Pharmacy, University of London, Dec. 10-13, 2011, London, UK, Abstract book:  page 63 (Poster Presentation).

                                                                    Honors & Awards

Scholarship award for higher education by the Ministry of Health and Medical Education of Iran, 1993-1996.

The Parke-Davis Centennial Pharmacy Research Award, 1996-1997 and 1997-1998.

The 13th Razi Research Festival on Medical Sciences, Second Rank in Modern Technology (Nanotechnology and Biotechnology), www.razi.hbi.ir, December 2007.

Members                                                  hip Membership

Editorial Board of:

            Directing Manager of Nanomedicine Journal

American Journal of Current Immunology

            ISRN Pharmaceutics

            BioImpact

SM Journal of Nanotechnology and Nanomedicine

                                                           Administrative Responsibilities

Founder of Exir Nano Sina Company:

Exir Nano Sina Company (ENSC, http://exirnanosina.ir) founded by Prof. Mahmoud R. Jaafari from School of Pharmacy, Mashhad University of Medical Sciences with the support of Iranian Nanotechnology Initiative Council in 2009. ENSC is a knowledge-based nanopharmaceutical company focused on the research, development and commercialization of innovative nanopharmaceutical products based on its proprietary drug delivery technologies. Our strengths lie in lipid-based formulation and scale-up for parenteral, oral and topical drugs using liposomes, micelles and nanoparticles to optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs.

ENSC produce PEGylated liposomal doxorubicin with the trade name of SinaDoxosome® for the treatment of cancer, Curcumin nanomicelles (SinaCurcumin®) as supplement and topical nanoliposomal Amphotericin B (SinaAmpholeish®) for the treatment of cutaneous leishmaniasis.

 

Patents:

1)      United States Patent Application Publication: 2015   Mahmoud Reza Jaafari, Ali Khamesipour,  TOPICAL LIPOSOMAL COMPOSITIONS FOR DELIVERING HYDROPHOBIC DRUGS AND METHODS PREPARING SAME, Publication Number: US 2015/0147382 A1.

2)      United States Patent Application Publication 2015  Amirhossein Sahebkar, Ali Badiee, Mahmoud Reza Jaafari,  METHOD AND COMPOSITION FOR TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES, Publication Number: US 2015/0147383 A1.

3)      United States Patent Application Publication: 2016   Mahmoud Reza Jaafari, Seyed Mahdi Rezayat, Javad Akhtari, TARGETING LIPOSOMAL COMPOSITION USING ANTI-HER2 AFFIBODY MOLECULES AND APPLICATIONS THEREOF IN CANCER TREATMENT, Publication Number: US 2016/0045614 A1.

4)      2015   Mahmoud Reza Jaafari, Seyed Mahdi Rezayat, Fatemeh Ghaibi, LONG CIRCULATING LIPOSOMES CONTAINING SILYBIN AND SILYMARIN AND USE THEREOF IN CANCER TREATMENT, Provisional Patent Application Number in USPTO: US 62245988.

5)      2015   Mahmoud Reza Jaafari, Seyed Mahdi Rezayat, Fatemeh Ghaibi, POLY ETHYLENE GLYCOL-PHOSPHOLIPID CONJUGATED MOLECULES WITH CYTOTOXIC EFFECTS, SYNTHESIZING THE SAME AND USE THEREOF IN CANCER TREATMENT, Provisional Patent Application Number in USPTO: US 62173941.

6)      2015   Mahmoud Reza Jaafari, Masoumeh Zahmatkeshan, Seyed Mahdi Rezayat, CANCER-TARGETED PEPTIDES AND APPLICATIONS THEREOF, Provisional Patent Application Number in USPTO: US 62217877.

7)      2015   Mahmoud Reza Jaafari, Shahrzad Amiridarban, Ali Badiee, TARGETING HDM2 EXPRESSING CANCER CELLS WITH A NOVEL PEPTIDE AND APPLICATIONS THEREOF IN CANCER TREATMENT, Provisional Patent Application Number in USPTO: US 62272701.

Professional Experience:

1988-1993:      Instructor of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

 

1999-2004:      Assistant Professor of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran                                          

 

2004-2009:       Associate Professor of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2009-:              Professor of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

 

2003-2004:      Dean of Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2004-2006:      Dean of Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2008-2010:      Director of Nanotechnology Council, Mashhad University of Medical Sciences, Mashhad, Iran

2010-:              Dean of Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2011-:              Head of Pharmaceutical Nanotechnology Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

2014-:              Head of Committee of Technologies and Innovations in Medical Researches, National Institute for Medical Research Development (NIMAD)

 

Other Skills

Teaching Responsibilities:

Various topics in pharmaceutics and Pharmaceutical Nanotechnology: Targeted drug delivery, Liposomal drug delivery, Gene Delivery, Nanopharmaceutics, NanoBiotechnology, and  Peptide and protein formulation and delivery

 

 

 

بازديدكنندگان

امروز: 44
ديروز:30
اين هفته: 242
هفته‌ي گذشته: 429
اين ماه: 1158
ماه گذشته: 1908

اوقات شرعی

دانشگاه علوم پزشکی مشهد | Mashhad University of Medical Sciences | جامعة مشهد للعلوم الطبية
تمام حقوق مادی و معنوی این سایت مربوط به دانشگاه علوم پزشکی مشهد می باشد. هرگونه کپی برداری از مطالب آن تنها با ذکر منبع بلامانع است.